What is the 13F Pro Quality Score for SOLV?

13F Pro ranks Solventum Corp (SOLV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SOLV's current score at https://13fpro.ai/research/SOLV (free sign-up required for the full ranking).

Where does 13F Pro source SOLV data?

All Solventum Corp fundamentals and ownership data come directly from SEC EDGAR. Solventum Corp files with the SEC under CIK 1964738. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SOLV in?

Solventum Corp (SOLV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SOLV research updated on 13F Pro?

SOLV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Solventum Corp(SOLV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1964738 SOLV stock profile & AI dashboard →

13F Pro Quality Score

55.7/100

Rank #1,148 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

21.0/100

Profitability

81.1/100

Balance Sheet

87.7/100

Earnings Quality

4.6/100

Free Cash Flow

25.5/100

Institutional Flow

65.5/100

Revenue Scale

84.6/100

Dilution Risk

41.9/100

SOLV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Solventum Corp (SOLV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SOLV at 55.7/100 on a 32-signal composite quality model, placing it at rank #1,148 of 2,879 stocks — the top half of the AI-ranked universe. SOLV scores in the top quartile across balance sheet strength (87.7), revenue scale (84.6), profitability (81.1). Areas of concern include earnings quality (4.6) and revenue growth (21.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 41.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Solventum Corp reports quarterly revenue of $2.0B, net income of $13.0M, free cash flow of $-273.0M. Top institutional holders of SOLV by reported 13-F value include Independent Franchise Partners LLP, BlackRock,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. SOLV trades on the NYSE exchange and files with the SEC under CIK 1964738. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SOLV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Solventum Corp directly from SEC EDGAR. Solventum Corp's 13F Pro composite quality score has ranged between 8 and 67 since 2025, currently 55.7 — a declining long-term trajectory across 40 quarterly and live scoring snapshots.

✦

Fun facts about Solventum Corp

Quirks, history, and lore behind SOLV — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mid-cap · listed on the NYSE · headquartered in Minnesota.
2
The Numbers
Generates roughly $8 billion in annual revenue across more than 160 countries — not bad for a company that only became independent recently.
3
The History
Spun off from a industrial-to-healthcare giant in 2024, it inherited decades of legacy business in medical and dental products that its former parent decided it no longer wanted.
4
The Secret
Its four core segments cover MedSurg, dental, health information systems, and purification solutions — basically a full hospital supply closet under one roof.
5
The Lore
Products you've almost certainly encountered in a clinic include wound care dressings, sterilization systems, and oral care items whose branding used to carry a very famous three-letter corporate parent's name.
6
The Giveaway
When 3M decided to focus on its core industrial and safety businesses, it carved out its entire healthcare division into this freshly minted standalone company in early 2024.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$2.0B

Net Income

Q1 2026

$13.0M

Free Cash Flow

Q1 2026

$-273.0M

D/E Ratio

Q1 2026

1.02

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+0.9% YoY

$8.32BFY 2025

FY22 $8.13BFY23 $8.20BFY24 $8.25BFY25 $8.32B

Net Income

+224.8% YoY

$1.56BFY 2025

FY22 $1.34BFY23 $1.35BFY24 $479.0MFY25 $1.56B

Operating Income

+110.5% YoY

$2.18BFY 2025

FY22 $1.69BFY23 $1.69BFY24 $1.04BFY25 $2.18B

EPS (Diluted)

+221.7% YoY

$8.88FY 2025

FY22 $7.78FY23 $7.79FY24 $2.76FY25 $8.88

Total Assets

-1.1% YoY

$14.29BFY 2025

FY22 —FY23 $13.94BFY24 $14.46BFY25 $14.29B

Total Debt

-40.1% YoY

$5.04BFY 2025

FY22 —FY23 $0.00FY24 $8.41BFY25 $5.04B

Op. Cash Flow

-68.9% YoY

$369.0MFY 2025

FY22 $1.68BFY23 $1.92BFY24 $1.19BFY25 $369.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$8.32B +0.9%	$8.25B +0.7%	$8.20B +0.8%	$8.13B	—
Net Income	$1.56B +224.8%	$479.0M -64.4%	$1.35B +0.2%	$1.34B	—
Operating Income	$2.18B +110.5%	$1.04B -38.8%	$1.69B -0.1%	$1.69B	—
EPS (Diluted)	$8.88 +221.7%	$2.76 -64.6%	$7.79 +0.1%	$7.78	—
Total Assets	$14.29B -1.1%	$14.46B +3.7%	$13.94B	—	—
Total Debt	$5.04B -40.1%	$8.41B	$0.00	—	—
Operating Cash Flow	$369.0M -68.9%	$1.19B -38.1%	$1.92B +14.1%	$1.68B	—

AI Insight: SOLV Financial Trends

Debt reduction accelerated sharply after Q3 2025's divestiture-driven gain, but Q1 2026 operating income collapsed to $81M with negative operating cash flow of -$189M.

• Total debt fell from $8,709M in Q3 2024 to $5,080M in Q1 2026, a $3.6B reduction driven largely by the Q3 2025 asset sale.

• Equity strengthened from $2,867M in Q2 2024 to $5,049M in Q4 2025, partly reflecting the Q3 2025 $1,266M net income spike.

• Operating income deteriorated to $81M in Q1 2026, the lowest in the dataset, down from $215M in Q2 2025.

• Revenue declined to $1,998M in Q4 2025 and $2,007M in Q1 2026, the two weakest quarters across the full period.

⚠ Operating cash flow turned negative at -$189M in Q1 2026 — first negative print in the dataset — signaling potential working capital stress.

⚠ Net income of $13M in Q1 2026 is the second-lowest in the period; sustainability of earnings ex-divestiture gains remains unproven.

⚠ Debt ticked up slightly to $5,080M in Q1 2026 from $5,035M in Q4 2025 — monitor whether deleveraging momentum has stalled.

AI Insight: SOLV Ratio Trends

Q3 2025 figures are heavily distorted by a one-time item, masking an underlying deterioration in Q4 2025 and Q1 2026 operating profitability.

• Operating margin collapsed to 4.0% in Q1 2026 from 10.0% in Q2 2025, the weakest quarterly reading in the observable period.

• D/E leverage fell sharply from 2.90 in Q2 2024 to 1.00 in Q4 2025, indicating meaningful debt reduction over the period.

• ROIC dropped to 3.2% in Q1 2026 from 66.8% in Q3 2025, though Q3 2025 was inflated by a one-time gain distorting all return metrics.

• NPM of 0.7% in Q1 2026 is the lowest quarterly reading outside Q4 2024's 1.5%, signaling persistent bottom-line pressure.

⚠ Q3 2025 OpMargin of 80.6% and ROE of 101.6% are clear one-off distortions; stripping them reveals no sustained profitability improvement.

⚠ Q1 2026 ROIC of 3.2% is the lowest quarterly figure recorded — monitor whether this trough reverses in coming quarters.

⚠ TTM OpMargin of 25.5% is flattered by the Q3 2025 anomaly; forward margins may print well below that TTM level.

Get alerted when SOLV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Solventum Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SOLV

Independent Franchise Partners LLP
$1.0B15,733,495 sh
BlackRock, Inc.
$684.3M10,478,972 sh
VANGUARD CAPITAL MANAGEMENT LLC
$627.0M9,601,949 sh
TRIAN FUND MANAGEMENT, L.P.
$537.9M8,236,753 sh
STATE STREET CORP
$418.4M6,407,480 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$417.3M6,390,364 sh
DAVIS SELECTED ADVISERS
$413.4M6,330,325 sh
GEODE CAPITAL MANAGEMENT, LLC
$309.3M4,752,260 sh
Boston Partners
$255.6M3,914,091 sh
Invesco Ltd.
$247.5M3,789,883 sh

Fund	Value	Shares
Independent Franchise Partners LLP	$1.0B	15,733,495
BlackRock, Inc.	$684.3M	10,478,972
VANGUARD CAPITAL MANAGEMENT LLC	$627.0M	9,601,949
TRIAN FUND MANAGEMENT, L.P.	$537.9M	8,236,753
STATE STREET CORP	$418.4M	6,407,480
VANGUARD PORTFOLIO MANAGEMENT LLC	$417.3M	6,390,364
DAVIS SELECTED ADVISERS	$413.4M	6,330,325
GEODE CAPITAL MANAGEMENT, LLC	$309.3M	4,752,260
Boston Partners	$255.6M	3,914,091
Invesco Ltd.	$247.5M	3,789,883

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SOLV on your watchlist

Track score changes the day Solventum Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SOLV a good stock to buy?

13F Pro's AI-powered analysis of Solventum Corp (SOLV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SOLV are available on the SOLV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SOLV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SOLV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Solventum Corp's investment landscape.